The trial continues to assess secondary endpoints, including long-term safety and overall survival. Credit: fernando zhiminaicela from Pixabay.

Novartis has announced that Lutathera along with octreotide long-acting release (LAR) has reduced the risk of disease progression or death in patients with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in a trial.

This was demonstrated in the Phase III NETTER-2 clinical trial, where the combination therapy extended median progression-free survival (PFS) to 22.8 months compared to 8.5 months with high-dose octreotide LAR alone.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial compared Lutathera plus octreotide LAR to high-dose octreotide in patients with advanced GEP-NETs. It included patients diagnosed with somatostatin receptor-positive (SSTR)-positive advanced GEP-NETs within six months before enrolment.

NETTER-2 is a landmark study, being the first to show positive results for a radioligand therapy (RLT) in a first-line setting.

During the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, data revealed a 72% reduction in the risk of disease progression or death when using Lutathera as a first-line therapy.

The safety profile of the therapy was consistent with previous findings, with most patients tolerating the full course of treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The NETTER-2 trial continues to assess secondary endpoints, including long-term safety and overall survival. This ongoing research is crucial for improving treatment strategies for patients with high-proliferation rate tumours.

Lutathera is already approved in the US, Europe, and Japan for certain types of GEP-NETs.

Novartis oncology development global head Jeff Legos said: “This is the first positive Phase III trial of a radioligand therapy in the first-line setting, and the overall efficacy and safety results are amongst the most clinically relevant observed to date in this kind of advanced cancer, addressing a significant unmet need for patients with newly diagnosed advanced GEP-NETs.

“The positive results are a significant advancement and further reaffirm our strategy to research and develop radioligand therapies in earlier lines of treatment or stages of disease to improve outcomes for patients.”